Arkolith/Insider Trading/ACAD/Form 4

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICERACADIA PHARMACEUTICALS INC (ACAD) · full profile →Form 4 · filed Apr 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$60K
Net Open-Market Flow
-$60K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 7, 2026Sell(S)3K$22.20$60K63K
Apr 5, 2026Option exercise(M)5K——66K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 5, 2026Option exercise(M)5K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001899977-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML